AbbVie acquires Penn spinoff Capstan for .1 billion to develop cell-based treatments for autoimmune diseases.
Discover how a University of Pennsylvania biotech company focused on treating autoimmune diseases through innovative cell reengineering is set to be acquired by pharmaceutical leader AbbVie for .1 billion.
